Kubli
n_Phase I human B CG challenge  trial                Page 1 of 41  
Version: 03/29/2022  FRED HUTCHINSON CANCER CENTER  
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE  
Current version: 03/29/2022  
Previous version :  
Title of Protocol:  
A Phase I single site open label clinical trial for the development of a human BCG challenge model to assess TB 
drugs  and vaccines  
Investigator s List  Professional Title  Phone Number  
Principal Investigator  
[INVESTIGATOR_349788], MD, MPH  Executive Director, HVTN  
Medical Director, Seattle MCTC  
Principal Staff Scientist, VIDD  
Clinical Professor, UW Global health  ([PHONE_7232]  
Investigators  
Chetan Seshadri , MD  Associate Professor, UW  Department of Medicine  
Associate Medical Staff, UW Medical Center and Harborview 
Medical Center  
Affiliate Investigator, VIDD, FHCRC  
Adjunct Professor, UW Department of Global Health  (206) 543 -6709
E.Chandler Church, MD, MSc Acting Instructor, UW Department of Medicine  
Senior Fellow, VIDD  (206) [ADDRESS_434849] Associate Professor , UW Department of Global 
Health  (206) 616 -4124
Sean C. Murphy, MD, PhD  Associate Professor, UW Laboratory Medicine  
Assistant Director, UW Medical Center  
Member, UW CERI D 
Clinical Investigator, Seattle MCTC  
Medical Director, Human Challenge Center, Seattle Children’s 
Research Institute  (206 ) 685 -6162
Jay Vary , MD, PhD Associate Professor, UW Division of Dermatology  ([PHONE_7233]  
David Sherman, PhD  Professor  and Chair, UW Microbiology  
Affiliate Professor, UW Global Health  ([PHONE_7234]  
Julie McElrath, MD, PhD  Senior Vice President and Director, VIDD; Member, VIDD  
Member, CRD  
Professor of Medicine, UW  
Adjunct Professor, Pathobiology, Global Health, and 
Laboratory Medicine , UW  
Joel D. Meyers Endowed Chair , FHCRC  ([PHONE_7235]  
Medical Monitor:  
Chetan Seshadri , MD  Associate Professor, UW  Department of Medicine ; Associate 
Medical Staff, UW Medical Center and Harborview Medical Center  
Affiliate Investigator, VIDD, FHCRC  
Adjunct Professor, UW Department of Global Health  (206) 543 -6709
Biostatistician:  
Andrew Fiore -Gartland , PhD Staff Scientist , VIDD  (206) 667 -1228
IRO received 05/20/22
FHCRC IRB Approval  
05/25/2022 
Document Released Date
 
Kublin_ Phase I human B CG challenge  trial                    Page 2 of 41    
Version: 03/29/[ADDRESS_434850] OF ABBREVIATIONS  ................................................................................................................................................... 8  
5.0 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ............................................................................................ 9  
5.1 Background Information  ...................................................................................................................................... 9  
5.1.1  The Challenge of Achieving TB Control ................................................................................................................ 9  
5.1.2  Evaluating New Vaccines for TB  ........................................................................................................................... 9  
5.1.3  Evaluating New Drugs for TB  ............................................................................................................................. 10 
5.1.4  The Need for a Human Challenge Model  ........................................................................................................... 10 
5.2 Rationale  ............................................................................................................................................................ 11 
5.3 Preclinical Data  .................................................................................................................................................. 11 
5.3.1  BCG  .................................................................................................................................................................... 11 
5.3.2  Isoniazid (INH)  .................................................................................................................................................... [ADDRESS_434851] ELIGIBLITY  ......................................................................................................................................................... 15 
8.1 Inclusion Criteria  ................................................................................................................................................ 15 
8.2 Exclus ion Criteria  ............................................................................................................................................... 16 
9.0 RECRUITMENT  ................................................................................................................................................................. 18 
10.0 STUDY PROCEDURES AND EVALUATIONS  ....................................................................................................................... 18 
10.1 Consent  .............................................................................................................................................................. 18 
10.2 Screening ........................................................................................................................................................... 18 
10.3 Group Assignment  ............................................................................................................................................. 19 
10.4 Study Drug Administration ................................................................................................................................. 19 
10.4.1  BCG injection (all participants)  .......................................................................................................................... 19 
10.4.2  INH (Group 1 only)  ............................................................................................................................................. 19 
 
Kublin_ Phase I human B CG challenge  trial                    Page 3 of 41    
Version: 03/29/2022  
 10.5 Study Duration  ................................................................................................................................................... 19 
10.6 Evaluatio ns ......................................................................................................................................................... 19 
10.6.1  Physical Examination and Clinical Assessments  ................................................................................................. 19 
10.6.2  Participant Self -monitoring AEs/SAEs and Health Status Records  ..................................................................... 19 
10.6.3  Concomitant Medication and Supportive Care Guidelines  ................................................................................ 20 
10.6.4  Laboratory Evaluations/As says  .......................................................................................................................... [ADDRESS_434852]  ..................................................................................................................................................... 21 
10.9 Memory Ai d eCRF Device and AE/SAE Recording Training  ................................................................................ [ADDRESS_434853] DISCONTINUATION OF ACTIVE TREATMENT  .................................................................................................... 25 
15.0 ASSESSMENT OF SAFETY  ................................................................................................................................................. 26 
15.1 Specification of Safety Parameters  .................................................................................................................... 26 
15.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters  ........................................... 26 
15.2.1  Adverse Events  ................................................................................................................................................... 26 
15.2.2  Reactogenicity  .................................................................................................................................................... 27 
15.2.3  Additional Adverse Event Characterization and Severity Grading  ..................................................................... 29 
15.3 Reporting Procedures  ........................................................................................................................................ 31 
16.0 DATA AND SAFETY MONITORING PLAN  .......................................................................................................................... 32 
17.0 DATA MANAGEMENT/CONFIDENTIALITY  ....................................................................................................................... 32 
17.1 Data Management Responsibilities  ................................................................................................................... 32 
17.2 Data Capture Methods  ...................................................................................................................................... 32 
17.3 Types of Data  ..................................................................................................................................................... 33 
17.4 Study Records Retention ................................................................................................................................... 33 
17.5 Quality Control  ................................................................................................................................................... 33 
18.0 STATISTICAL CONSIDERATIONS  ....................................................................................................................................... 33 
18.1 Sample Size and Power for Outcome Measures  ................................................................................................ 33 
18.2 Randomization  ................................................................................................................................................... 34 
18.3 Ethnic and Gender Distribution Chart  ................................................................................................................ 34 
19.0 ETHICS/PROTECTION OF HUMAN SUBJECTS ................................................................................................................... [ADDRESS_434854]  ................................................................................................................................. 35 
19.2 Informed Consent Process  ................................................................................................................................. 35 
 
Kublin_ Phase I human B CG challenge  trial                    Page 4 of 41    
Version: 03/29/[ADDRESS_434855] Confidentiality  ....................................................................................................................................... 36 
19.5 Future Use of Stored Specimens and Data  ........................................................................................................ 36 
20.0 PUBLICATION POLICY  ...................................................................................................................................................... 36 
21.0 REFERENCES  .................................................................................................................................................................... 36 
22.0 APPENDICES  .................................................................................................................................................................... 39 
Appendix A: Lab Procedures Table  ...................................................................................................................................... 40 
Appendix B: Participant Procedures Table  .......................................................................................................................... 41 
 
 
  
 
Kublin_ Phase I human B CG challenge  trial                    Page 5 of 41    
Version: 03/29/2022  
 1.0 PROTOCOL SYNOPSIS  
Protocol Title  A Phase I single site open label clinical trial for the development of a human 
BCG challenge model to assess TB drugs and vaccines  
Trial Phase  Phase 1  
Study Objectives  Primary : 
1. Evaluate the safety and tolerability of Intradermal Tice® BCG 
followed by a short course (3 days) of isoniazid (INH).  
2. Assess the BCG bacterial burden in skin biopsies as measured by 
[CONTACT_921].  
Secondary : 
1. Assess the BCG bacterial burden in skin biopsies as measured by a novel qPCR assay.  
2. Evaluate peripheral blood cellular frequencies  (Trucount) after  
intradermal BCG.  
3. Evaluate adaptive immune response after  intradermal BCG 
(validated intracellular cytokine staining after stimulation). 
Exploratory  
1. To conduct analyses related to furthering the understanding of TB, 
immunology, vaccines, and clinical trial conduct.  
 
Outcome Measures  Primary Endpoints:  
1. The rate of AE’s/SAE’s  
2. Colony forming units (CFU) from culture  
Secondary Endpoints:  
1. Quantitative bacterial 16S r ibosomal DNA PCR  
2.  Microbial viability testing pre -ribosomal RNA RT -PCR 
3. Humoral and cellular immune responses after BCG immunization 
Summary of Study Design  This is phase 1 , open -label, randomized clinical protocol  to develop a human 
challenge model using the licensed and available BCG VACCINE USP (TICE® 
strain) with and without  antibacterial Isoniazid (INH).  It will involve [ADDRESS_434856] ion of  BCG; five of these participants will receive oral INH for 3 days.  
Participants will undergo physical exams, clinical evaluations, blood draws, urine collections, skin biops ies, and pregnancy tests.   This study will measure 
the rate of replication by [CONTACT_349799] , systemic innate 
and adaptive immune responses, including humoral and cellular assay analyses and the  evaluation and [COMPANY_003]/IGRA status . 
Population  10 healthy male and non -pregnant female individuals, HIV and TB 
uninfected, aged 18 to 45 years, with no extensive residence in high TB 
endemic country.  
 
Kublin_ Phase I human B CG challenge  trial                    Page 6 of 41    
Version: 03/29/2022  
 Drugs  • BCG VACCINE  USP (TICE® strain)  has been licensed for percutaneous use 
and is an attenuated, live culture preparation of the Bacillus of 
Calmette and Guerin (BCG) strain of Mycobacterium bovis.  
• Isoniazid is a licensed antibacterial available as 100mg and 300mg 
tablets for oral administr ation.  
Dose  Ten participants  will receive one intradermal injection of 2x106 cfu Tice® BCG 
(ID), and five of these participants will receive  oral tablet (s): either three 
table ts of 100mg or one  tablet of  300mg of INH each day for 3 days 
following the injection of BCG vaccine . 
Duration of Participation 16 to 24 weeks (screening up to 8 weeks prior to enrollment, study follow up 
for 16 weeks after enrollment)  
2.0 STATEMENT OF COMPLIANCE  
 
The trial will be conducted in accordance with International Conference on Harmonisation Good Clinical Practice 
(ICH GCP), applicable [LOCATION_002] (US) Code of Federal Regulations (CFR), Office for Human Research Protections (OHRP), IRB policies of Fred Hutchinson Cancer Cente r, and collaborating institutions .  The Principal 
Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement from the Investigational New Drug (IND)  (If applicable), funding agency and documented app roval 
from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.  All personnel involved in the conduct of this study have completed Human Subjects Protection 
and ICH GCP Training.  
 The protocol, informed consent form, recruitment materials, and all participant materials will be submitted to the IRB for review and approval.  Approval of both the protocol and the consent form must be obtained before any participant is enrolled.  Any am endment to the protocol will require review and approval by [CONTACT_142286].  All changes to the consent form will be IRB approved; a determination will be made regarding whether a new consent needs to be obtained fr om participants who 
provided consent using a previously approved consent form.  
   
 
Kublin_ Phase I human B CG challenge  trial                    Page 7 of 41    
Version: 03/29/2022  
 3.0 SIGNATURE [CONTACT_349833], including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal 
regulations and ICH guidelines.  
 
   
James Kublin, MD., MPH.  
Principal Investigator   [INVESTIGATOR_349789]_ Phase I human B CG challenge  trial                    Page 8 of 41    
Version: 03/29/[ADDRESS_434857]/RR -TB Multidrug and Rifampi[INVESTIGATOR_2513] -resistant Tuberculosis  
MOP  Manual of Procedures  
MTB  Mycobacterium Tuberculosis  
N Number (typi[INVESTIGATOR_19737])  
NIAID  National Institute of Allergy and Infectious Diseases, NIH, DHHS  
NIH National Institutes of Health  
NK Natural Killer  
OCRA  Office of Clinical Research Affairs, DMID, NIAID, NIH, DHHS  
OHRP  Office for Human Research Protections  
ORA  Office of Regulatory Affairs, DMID, NIAID, NIH, DHHS  
OTC Over the Counter  
PBMC  Peripheral Blood Mononuclear Cell  
PoD Prevention of Disease  
PoI  Prevention of Infection  
PoR Prevention of Relapse  
[COMPANY_003]  Purified Protein Derivative  
PI [INVESTIGATOR_349790] – PCR Reverse -Transcription Polymerase Chain Reaction  
SAE Serious Adverse Event  
Seattle MCTC  Seattle Malaria Clinical Trials Center  
SMC  Safety Monitoring Committee  
SRC Scientific Review Committee  
 
Kublin_ Phase I human B CG challenge  trial                    Page 9 of 41    
Version: 03/29/2022  
 TB Tuberculosis  
WBC  Whole Blood Cell  
WHO  World Health Organization  
 
 
5.0 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
 
5.1 Background Information  
 
5.1.1 The Challenge of A chieving TB Control  
Tuberculosis (TB) can be diagnosed, treated  and prevented, yet TB is the leading cause of death 
from an infectious agent globally, accounting for ~1.6 million deaths in 2016 - [ZIP_CODE].  It is also 
the leading cause of death among people living with HIV, totaling 300,000 deaths in 2016  - 2017.  
The Wo rld Health Organization (WHO) estimated that in 2017, 10 million people developed 
active tuberculosis (36% in women; 9% in people living with HIV; 72% living in Africa), causing substantial global morbidity and renewing the source of transmission
2.  Multid rug and 
rifampi[INVESTIGATOR_2513] -resistant tuberculosis (MDR/RR -TB) remains a global health threat with an estimated 
558,[ADDRESS_434858]/RR -TB cases in [ZIP_CODE].  There are an estimated 1.7 billion people (23% of the 
world’s population) that are latently infected with Mycobacterium tuberculosis  (MTB ), from 
which cases of active TB disease arise.  While the WHO has set a target for ending the TB 
epi[INVESTIGATOR_251727] 2030, progress has been inadequate, with TB rates declining at a rate of 2% per year
4.  Although effective TB therapi[INVESTIGATOR_123325], the impact on the global TB epi[INVESTIGATOR_349791].  TB treatment, particularly for multidrug resistant TB, is long, toxic, has drug -drug 
interactions with antiretroviral drugs and suboptimal adherence.  Effective TB vaccines that 
prevent TB inf ection, disease, and recurrence are essential to eliminate TB globally, and may 
prove to be effective against drug susceptible and resistant forms of TB, as the genetic mutations that confer resistance are not likely to alter susceptibility to immunological activity.  
 
5.1.2 Evaluating New Vaccines for TB  
Although BCG ( Mycobacterium bovis  Bacillus Calmette -Guerin) vaccination offers some 
protection against TB in some populations, its efficacy is suboptimal, variable, and not adequate for disease control
5.  The correlates of protective immunity and the reason for BCG’s variable 
and partial efficacy are unknown.  Very few studies have examined the immune correlates of 
risk associated with BCG vaccination.  Development of a more effective TB vaccine is a high priority in global health.   
 
The complexity of TB pathogenesis and immunology has le d to the identification of several 
different populations that could be targeted for evaluations of TB vaccines.  Ultimately, the 
objective of a TB vaccine is prevention of microbiologically confirmed TB disease (PoD).  
Recently a Phase 2b study showed that  M72/AS01E conferred an estimated 54% efficacy against 
disease among latently infected individuals
6.  This is an exciting result for the field, though with 
only 32 primary cases , a Phase 3 PoD study and immunological correlates analyses will be 
needed for validation.  Prior to this study, the low incidence of TB disease spurred HVTN and TB 
collaborators to advocate for screening vaccine candidates based on efficacy in the prevention 
of infection (PoI)7.  Due to the higher incidence of infection compared to disease, such a trial can 
efficiently move forward promising vaccines that elicit functional immunological responses against the pathogen, mitigating risk of a large future PoD trials.  In [ADDRESS_434859] PoI 
study showed that BCG re -vaccination can prevent sustained MTB infection
8, generating 
 
Kublin_ Phase I human B CG challenge  trial                    Page 10 of 41    
Version: 03/29/[ADDRESS_434860] treatment for active TB disease are at a much higher risk of 
relapse or reinfection9.  Modeling suggests that therapeutic TB vaccines (PoR) may not only 
reduce recurrence, shorten treatment a nd decrease post treatment morbidity via immune -
mediated mechanisms, but may also serve as a unique setting to discover immune correlates of protection that could be applied generally to preventive vaccines.  Thus, there are several 
promising avenues for TB vaccine development, but stage -gating strategies for down -selecting 
the most promising candidates are still lacking.  
 
5.1.[ADDRESS_434861] of a new agent in TB patients involves the early bactericidal activity (EBA).  In this test, a patient receives a new agent as monotherapy for 2, 7, or 14 days, 
and the decrease in bacterial colony forming units (CFU) in sputum is determined.  While the 
original purpose of the assay was dose finding
11, the EBA is now employed as a gating tool to 
predict drug efficacy in humans.  Unfortunately, the predictive power of this test is notably 
poor12.  For but one example, the recently approved new TB drug bedaquiline was nearly 
shelved prematurely due to disappointing results in the EBA13.  In response, field experts have 
called for development of “novel, more efficient screening trial designs” to expand the throughput and accuracy of phase [ADDRESS_434862] University has already created a precedent of BCG challenge studies in animals 
 
Kublin_ Phase I human B CG challenge  trial                    Page 11 of 41    
Version: 03/29/2022  
 and humans  (see below). We propose a phase 1 trial to analyze the local and systemic immune 
response to intradermal BCG and the effects of approved drugs with known microbicidal 
activity.  This study design will demonstrate the capabilities of our local infrastructure and expertise in TB immunology and microbiology.  The trial will illuminate the nature of local and systemic immune responses to BCG and treatment response, as well as demonstrate our l ocal 
capacity for newer, more innovative study designs.   
5.2 Rationale  
 
We propose to develop a BCG challenge model for use in short term Phase I human trials capable of assessing the ability of TB drugs and/or vaccine -induced immune responses to impact  in vivo 
mycobacterial replication as a method of assessing antimycobacterial agents and/or protective immunity  elicited by [CONTACT_349800] -directed therapy .   We are well equipped to implement efficient 
and successful TB drug and vaccine trials, leveraging our extensive experience with the Seattle Malaria 
Clinical Trials Center and our collaborations with colleagues at the University of Washington, Seattle Children’s  Research Institute, the Infectious Disease Research Institute, as well as TB investigators 
globally.   This demonstration of BCG as a candidate TB challenge agent will provide our respective 
investigators and institutions experience and data for future work.  
 
5.[ADDRESS_434863] , which was similar in 
magnitude to that seen in an aerosol MTB  infection model.  Tog ether, these data provide 
support the further development of a human BCG infection model to evaluate new drugs and vaccines.  
 
5.3.2 Isoniazid (INH)  Since its introduction in 1954, isoniazid has been a cornerstone of frontline TB treatment in humans.  It has also been tested in numerous animal models of TB infection including mice
16, 
guinea pig17, zebrafish18, and nonhuman primates19.  BCG vaccination is both safe and efficacious 
in conjunction with INH treatment in animal models20, 21.  In culture, BCG is as sensitive to INH as 
is M. tuberculosis22.  These data suggest that INH provides an excellent opportunity to test novel 
approaches to measuring ant i-TB drug efficacy in humans.  
 
5.3.3 Novel Pre-ribosomal RNA A ssay to A ssess the Viable BCG Bacterial Burden in Skin Biopsies  
Mycobacterial 16S ribosomal RNA (rRNA) is a sensitive indicator of the presence of BCG but  does 
not completely discriminate between viable and non -viable organisms.  To obtain more 
discriminating data for this viable/non -viable distinction, testing for labile pre -rRNA was 
explored. Like other bacteria, M. tuberculosis  was known to transiently express pre -rRNAs that 
could be measured by [CONTACT_349801] (RT -PCR) vs. PCR -only assay for a 
pre-rRNA region of the 16S rRNA23,24.  In vitro s tudies have been performed in -house (Murphy 
Laboratory) to hold 2x106 cfu BCG in nutrient -depleted conditions (PBS), nutrient -limited 
conditions (human serum) or nutrient -rich conditions (7H9 broth media) for four days with or 
 
Kublin_ Phase I human B CG challenge  trial                    Page 12 of 41    
Version: 03/29/2022  
 without isoniazid.  After fou r days, 1% of the material (intended to mimic the biopsy recovery of 
BCG at the administration site), was diluted into drug- free 7H9 media and monitored by [CONTACT_094] -
rRNA molecular viability testing and by [CONTACT_349802] [ADDRESS_434864] study, they tested variations in the source of 
BCG and challenge dose27.  Since intradermal challenge may not be physiologically relevant for a 
pulmo nary infection, they are now testing aerosol BCG challenge in humans (ClinicalTrials.gov 
[STUDY_ID_REMOVED]).   
 
 Another group that has published in this area is led by [INVESTIGATOR_124]. Dan Hoft at St. Louis University, though the 
focus of their efforts has been bacterial pe rsistence and shedding.  In their first study, they performed 
serial punch biopsies adjacent  to the site of BCG vaccination (rather than in the center of the lesion) in 
order to quantify mycobacterial shedding using PCR and solid culture28.  More recently,  they repeated this 
study using swabs to measure shedding non -invasively by [CONTACT_349803] (solid culture, liquid 
culture, and quantitative PCR)29. 
 Together, these studies validate the feasibility and safety of our proposed study.  
 
5.5 Protocol  Agent s  
 
• BCG vaccine  (Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis ): one 
intradermal injection of on -label dose of 2x106 cfu Tice® BCG  
• Isoniazid (INH) : oral tablets of on-label standard dose of either three 100mg  tablets  (300mg) or 
one 300mg table t for [ADDRESS_434865] BCG injection . 
5.6 Handling, Storage and Accountability  and Preparation 
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 13 of 41    
Version: 03/29/[ADDRESS_434866] people will develop a small swelling (nodule) at the injection site that break open, release pus or 
blood -tinged discharge, and form an ulcer the size of a dime.  The ulcer will heal over a period of 
weeks and forms a scar that remains for life.  Occasionally , lymph nodes around the vaccination 
site can become tender to touch .  “Flu- like” symptoms that are common to many vaccines 
includes fevers, chills, loss of appetite, muscle aches, and generally not feeling well can last 1 -2 
days.  
 A very small number of people (1 in 4 million) have an immediate allergic reaction to BCG.  Symptoms include rash, swelling around the mouth, difficulty breathing.  These can be treated with emergency medications.  If severe, they can cause death.  
 
There is a risk that by [CONTACT_349804], participants may develop a false positive 
tuberc ulin skin test ( [COMPANY_003]) that will complicate the early diagnosis and treatment of latent 
(inactive) TB.  However, a diagnosis of latent TB can be confirmed by [CONTACT_329508], including a clinical examination, chest x -ray, and blood test (IFN- g release assay).  
 
Risks of Isoniazid (INH)  
Participant s who are administered Isoniazid may experience some side effects that include:  
numbness and tingling in the extremities, hepatitis (symptoms include  loss of appetite, nausea, 
vomiting, fatigue, malaise, and weakness ), nausea, vomiting, upset stomach, fever, and rash . 
 
Participants  will be closely monitored by [CONTACT_349805].  
 
Risks of Intradermal Injection  
Participant s may experience: pain, swelling, redness, itching caused by [CONTACT_349806]. There is 
potential for an infection at the ID challenge site. 
 
Risks of Skin Biopsy  
Participants may experience: pain, swelling, redness, bleeding and bruising at the biopsy site  
during and a day or two after , damage to the skin such as artery or nerve and possible scarring .  
There is potential for an infection at biopsy site  or allergic reaction to the anesthetic  or gel foam 
 
Kublin_ Phase I human B CG challenge  trial                    Page 14 of 41    
Version: 03/29/2022  
 used to close the biopsy site . Participant s cannot swim  in a chlorinated water until the gel foam 
has sufficiently close d the biopsy area.  
 
Risks of Blood Draws  
Participants may experience: pain, swelling, redness, caused by [CONTACT_349807], 
nausea, light headed ness  and there is a slight chance of fainting.  There is potential for an 
infection at the needle insertion site   
 
Risks of [COMPANY_003] Skin Test  
Participants may experience: pain, swelling, redness, itching caused by [CONTACT_349808]/or [COMPANY_003] agent. There is potential for an allergic reaction to the agent and/or infection 
at the [COMPANY_003] test  site. 
 
Risk of the loss of confidentiality  
There is a potential for the loss of confidentiality. Each member of the research team has complete d human subjects prote ctions, and HIPAA and confidentiality training.   Trainings inform 
the research team members to follow confidentiality policies and best practices  when handling 
identifiable information.  
 
5.8.[ADDRESS_434867] benefit to participants in this study.  Others in the future may  benefit  
from the information gained from this research, which will help scientists develop a better TB 
vaccine.  
 
 
6.0 OVERVIEW OF CLINICAL TRIAL  
6.1 Study Objectives  
 
6.1.1 Primary Objectives  
• Evaluate the safety and tolerability of Intradermal Tice® BCG followed by a short course (3 
days) of isoniazid (INH).  
• Assess the BCG bacterial burden in skin biopsies as measured by [CONTACT_921].  
6.1.2 Secondary Objectives  
• Assess the BCG bacterial burden in skin biopsies as measured by a novel qPCR assay.  
• Evaluate peripheral blood cellular frequencies (Trucount) after  intradermal BCG.  
• Evaluate adaptive immune response after intradermal BCG (validated intracellular cytokine 
staining after stimulation) . 
6.1.3 Exploratory Objectives  
• To conduct analyses related to furthering the understanding of TB, immunology, 
vaccines, and clinical trial conduct.  
6.2 Study Design  
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 15 of 41    
Version: 03/29/2022  
 This Phase I single site open -label clinical trial will evaluate the use of Tice® BCG in healthy adult 
participants  as a challenge model for future assessment of TB drugs . Subjects (N=10) will be divided into  
two groups, where group [ADDRESS_434868] BCG injection and 
group 2 (control arm) will not receive any treatment. All groups will receive a d ose titration of 2x106 cfu 
of Tice® BCG intradermally  as noted in the following table:  
 
 Group 1  Group  2 
N 5 5 
Tice® BCG Dose  2x106 cfu 2x106 cfu 
INH Dose  300 mg /[ADDRESS_434869] follow -up clinic visits that will include: clinical assessments, AE/SAE review, ID 
challenge assessments, blood draws for immunogenicity and mycobacteria assays, skin biopsies, general 
exams and [COMPANY_003] skin testing.  
 
 
7.[ADDRESS_434870] meet all of the following criteria to participate  in this study.  
 
1. Provide written informed consent prior to initiation of any study procedures , 
2. Are males or non-pregnant females between the ages of 18 and 45 years, inclusive , 
3. Women of childbearing potential* in sexual relationships with men must use an acceptable  
method of preventin g conception** from 30 days prior to 3 months after Tice® BCG 
administration , 
*Not sterilized via tubal ligation, bilateral oophorectomy, hysterectomy or successful Essure®  
placement (permanent, non- surgical, non- hormonal sterilization) with documented radiological  
confirmation test at least 90 days after the procedure, and still menstruating or < [ADDRESS_434871] menses if menopausal).  
**Includes, but is not limited to, sexual abstinence, monogamous relationship with vasectomized  
partner who has been vasectomized for [ADDRESS_434872] receiving Tice®  
BCG, barrier methods such as condoms or diaphragms with spermicide or foam, effective  
intrauterine devices, NuvaRing ®, and licensed hormonal methods such as implants, injectables  
or oral contraceptives (“the pi[INVESTIGATOR_4382]”).  
Kubl
in_Phase I human B CG challenge  trial                Page 16 of 41  
Version: 03/29/[ADDRESS_434873] within 24 hours prior to enrollment and Tice® BCG administration ,
5. Are in good health, as judged by [CONTACT_349809] (oral
temperature, pulse, and blood p ressure), medical history and physical examination ,
6. Have a negative HIV -[ADDRESS_434874] a negative QuantiFERON -TB Gold test,
9. Negative is defined as Nil respon se < 0.8 IU/ml and TB Antigen response minus Nil response
<0.35 IU/mL or TB Antigen response minus Nil response > 0.35 IU/mL and < 25% of Nil responseand Mitogen response minus Nil response > 0.5 IU/ml ,
10. Have a urine dipstick for protein less than [ADDRESS_434875] any systemic symptoms* within 72 hours before Tice BCG administration or signs of  
lymphadenopathy, hepatosplenomegaly, or pulmonary disease by [CONTACT_349810],
*Includes fever, chills, malaise, fatigue, headache, night sweats, weight loss, nausea, vomiting, 
bleeding,  diarrhea, abdominal pain, rhinorrhea,  cough, wheezing,  or shortness of breath.
3. Have history of any significant acute or chronic medical conditions* or need for chronic  
medications that, in the opi[INVESTIGATOR_871], will interfere with immunity or affect  safety,
*Includes, but is not l imi ted to, di sorders of the liver,  kidney, l ung, heart, or nervous system, or  
other metabolic or autoimmune/inflammatory conditions. Have any hi story  of excessive scarring  
or keloid formation.
4. Have household contact [CONTACT_349811] i nvolving significant contact [CONTACT_349812],
*Includes persons with HIV, AIDs, or active cancer; infants (children < 1 year); pregnant women;  
or persons who are immunosuppressed for approximately 6 weeks (during the time of active ID  
lesion drainage).
5. Have a history of epi[INVESTIGATOR_002] (does not include febrile seizures as a child),
6. Have
 a pacemaker, prosthetic valve, or implantable cardiac devices,
7. Have a history of bleeding disorder,
8. Have a known allergy to any Tice BCG components (glycerin, asparagine,  citric acid, potassium  
phosphate, magnesium sulfate,  iron ammonium citrate, and lactose),
9. Received blood products or i mmunoglobulin within 6 months prior to Tice BCG administration,
10. Received immunotherapy within one year prior to Tice BCG administration,
11. Received or plan to receive live attenuated vaccines 4 weeks before or after Tice BCG  
administration,
12. Received or plan to receive inactivated or killed vaccines 2 weeks before or after Tice BCG  
administration,
Kubl
in_Phase I human B CG challenge  trial                Page 17 of 41  
Version: 03/29/2022  13. Plans to enroll in another clinical trial* that could interfere with safety assessment of the  
investigational product at any time during the study period,
*Includes trials that have a study i ntervention such as a drug, biologic,  or device.
14. Received an experimental agent* within 30 days prior to Tice BCG administration or planned  
receipt of an experimental agent within 90 days after Tice BCG administration,
*Includes vaccine, drug,  biologic,  device,  blood product, or medication.
15. Have a history of use of a systemic antibiotic within [ADDRESS_434876] long term use* of high dose oral or parenteral glucocorticoids**, or high-d ose i nhaled  
steroids***.
*Defined as taken for [ADDRESS_434877] 2 months.
**High dose defined as prednisone ≥ 20 mg total daily dose,  or equivalent dose of other  
glucocorticoids.
***High dose defined as > 800 mcg/day of beclomethasone dipropi[INVESTIGATOR_117476]. If short  
term corticosteroids are given, then the subject should not receive Tice® BCG or have blood  
collected for immunogenicity studies within [ADDRESS_434878] immunosuppression or are taking systemic immunosuppressants as a result of an  
underlying illness or treatment,
21. Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 36 months prior to Tice®  
BCG administration,
22. Any active neoplastic disease,
23. Have a pulse rate less than [ADDRESS_434879] a WBC less than 4.0x103/uL or greater than 10.5x103/uL,
27. Have hemoglobin l ess than 11.5x103/uL (female) or less than 12.5x103/uL (male),
28. Have a platelet count less than 140x103/UL,
29. Have a creatinine greater than 1.30 mg/dL,
30. Have an ALT (SGPT) greater than 40 IU/L (female) or greater than 55 IU/L (male),
31. Have known HIV, Hepatitis B, or Hepatitis C infection,
32. Have a history of alcohol or drug abuse in the last [ADDRESS_434880] or received BCG vaccine (BCG vaccination history 
wil
l be determined by [CONTACT_6270]-r eport, country of birth, and/or evidence of BCG scar),
34. Have a BMI >35,
35. [COMPANY_003] skin test within 2 months prior to Tice BCG administration or planned receipt during the  
study other than from participation i n this study,
36. Oral temperature ≥ 100.4°F  (≥ 38.0°C) or other symptoms of an acute illness within 3 days  
before Tice BCG administration. (Subject may be rescheduled),
37. Any medical disease or condition that, in the opi[INVESTIGATOR_871], is a contraindication to  
study participation*,
*Includes medical di sease or condition that would place the subject at an unacceptable risk of  
injury, render them unable to meet the requirements of the protocol,  or may interfere with the  
evaluation of responses or their successful  completion of the study.
 
Kublin_ Phase I human B CG challenge  trial                    Page 18 of 41    
Version: 03/29/[ADDRESS_434881] unable to meet the requirements of the 
protocol or compromise the interpretation of data or the scientific integrity of the protocol.   
 
 
9.0 RECRUITMENT  
 
Participants will be recruited from the Seattle King County area.  Recruitment materials may be posted in community areas such as, but not limited to: the campuses of Fred Hutchi nson and University of Washington, 
and community businesses that allow the pos ting of flyers.  Enrollment may also come from participants of 
other research studies and registries.    All recruitment methods and will be reviewed and approved by [CONTACT_349813] .  The 
participants from other studies or reposit ories must have granted consent  to allow being contact[CONTACT_349814].  The method of contact [CONTACT_349815]’s approval  per the 
other research studies protocols and registries as they may have certain limitations.   The gender and ethnic and racial demographics will reflect the Seattle King County community at large.  
10.0 STUDY PROCEDURES  AND EVALUATIONS  
 
10.1 Consent  
 
Informed consent i s a process that is initiated prior to the individual’s agreeing to participate in the 
study and continu ing throughout their  study participation.   The consent process will include the 
explanation of the research study to the participant and answer any ques tions that may arise.  The study 
team member who conducts the consent process will be medically qualified to answer any health 
concerns , risks and possible benefits of participation in this study .  The consent form  will be provided to 
the subject  which they may share with their families . The consent form  describe s in detail the study 
procedures and risks.   The participant will be given an adequate amount of time to review the c onsent 
form  prior to giving consent by [CONTACT_303393] .  Consent forms are IRB reviewed and approved prior to 
being distributed to participants. They are written documentation of informed consent and the 
participant is required to sign it prior to enrolling in the study .  The subjects may withdraw consent at 
any time througho ut the course of the study.  A copy of the informed consent document will be given to 
the participants  for their records.  
 
10.2 Screening  
 
Those who consent will be considered for eligibility and will undergo evaluations and assessments 
(screen ing process ).  Screening procedures include review of the participant’s  medical history  and 
concomitant medications , and collecting their vital signs (oral temperature, pulse, blood pressure)  and 
height and weight  (to calculate BMI) .  The Participant will unde rgo a  physical examination within 42 days 
prior to receiving Tice® BCG.  Female participants  of childbearing potential must have a negative serum 
pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to enrollment and 
receip t of Tice® BCG.  Participants  must have a urine dipstick for protein < 1 and negative for glucose at 
 
Kublin_ Phase I human B CG challenge  trial                    Page 19 of 41    
Version: 03/29/[ADDRESS_434882] their blood drawn via venipuncture to be  screened for HIV, hepatitis B 
surface antigen, antibody to hepatitis C virus, and QuantiFERON® -TB Gold Test.  Results of these 
screening tests must be negative.  
 
 
10.3 Group Assignment  
 
After the participant meets enrollment criteria, they are randomly assigned  by a computer program  to 1 
of the 2 groups.   In both groups, participants  will be immunized intradermally with a single dose of 2x106 
cfu Tice® BCG. 
 
• Group 1 subjects will receive INH dosages on Day s 4, 5, and 6. 
• Group 2 (control arm) will not receive INH.  
10.4 Study Drug Administration 
 
Tice® BCG and INH preparations will be performed by [CONTACT_349816] a study clinician licensed to administer study product.  
10.4.1  BCG injection  (all participants)  
One intradermal injection of Administration of BCG 2x10
6 cfu Tice® BCG in the deltoid region,  
Following administration of Tice® BCG, intradermal (ID) site reactions will be assessed for at least 30 minutes.  
10.4.2  INH (Group 1  only ) 
For the 5 participants assigned to Group 1, they will take INH: oral tablets of either three 100mg 
tablets (300mg) or one 300mg table t on days  4, 5, and [ADDRESS_434883] BCG dosing . 
10.5 Study Duration  
 
The participant s will come to the study clinic 1 7 times to undergo study procedures.  A dditional visits  
may be required  if they experience an abnormal ID challenge site.  The maximum study duration  will be 
22 weeks (about 6 months).  A screening visit, BCG dosing visit and 15 follow up visits  within 4 months 
will occur after skin biops y.  
 
10.6 Evaluations  
 
10.6.1  Physical Examination and Clinical Assessments  
A physical examination will be performed within 42 days prior to getting BCG and at the final 
study visit .  Participant s medical history, concomitant medications, their vital signs (oral 
temperature, pulse, blood pressure), and height and weight (to calculate B ody Mass Index 
(BMI) ) will be collected.  Participants will be assessed for lymphadenopathy if indicated based on 
review of interim medical history and clinical assessment.  A medically licensed research team 
member will review the participants health status and eligibility at the clinic visits.   
   
10.6.2  Participant Self-monitoring AEs/SAEs and H ealth Status Records  
Partic ipants  will be asked to record their solicited local and systemic reactions, any unsolicited 
AEs/SAEs  (pain, tenderness and drainage)  and concomitant medications throughout the study.  
 
Kublin_ Phase I human B CG challenge  trial                    Page 20 of 41    
Version: 03/29/[ADDRESS_434884] AEs/SAEs.  
 
10.6.3  Concomitant Medication and Supportive Care Guidelines  
At each study visit/contact, the investigator will ask the participant s about any medication 
taken, including herbals, vitamins and holistic/naturopathic medications , concomitant 
medication, including vaccines, and any other medication relevant to the protocol, including any 
specifically contraindicated will be recorded in the e CRF device with trade name [INVESTIGATOR_1238]/or generic 
name [CONTACT_11889], medical indication, start and end dates of treatment.  Concomitant 
medications will include but are  not limited to:  
 
• Antibiotics,  
• Over the counter (OTC)  
• Prescription meds.  
10.6.4  Laboratory Evaluations/Assays  
Whole blood samples will be collected via venipuncture for clinical safety laboratory evaluations and BCG response assays.  A total of ~ 730mls (~3 cups) will be drawn for the entire study.   At 
the screening visit (visit 1) and Days 0  (visit 2) , 1 (visit 3) , 2 (visit 4) , 3 (visit 5) , 4 (visit 6) , 8±1 (visit 
7), 15±1 (visit 8) , 28±1 (visit 9) , 56±2 (visit 10) , 84+3 (visit 11) , 98+1 (visit 12) , 112+1 (visit 14) , 
and 114+1 (visit 15) , these standard blood draws will be collected from each participant to 
perform immunogenicity and humoral assays.   
 
Clinical safety assessments 
Blood samples for clinical safety laboratory evaluations (WBC, hemoglobin, platelet count, ALT 
(SGPT), creatinine) will be collected from each subject prior to administration of Tice® BCG at 
the screening visit (visit 1) .  These parameters must meet protocol -defined eligibility criteria to 
be enrolled and receive Tice® BCG . Additional clinical safety labora tory evaluations may be 
deemed necessary during the study.  
 
Measuring BCG response 
 Skin biopsy  (via XX) 
Skin biops ies will be taken to quantify  BCG bacteria. The ID challenge site will be biopsied on 
Days 3, 8, 15 and 56 (visit s 5, 9, 10, and 1 2) after Tice® BCG administration.  A 4mm skin 
biopsy using the punch  method will be taken at the ID challenge site. A local anesthetic 
injection will be given to numb the site. Gel foam will be used to close the biopsy area. A 
medically licensed research team member will perform the biopsy.  
 The number of viable BCG bacteri a will be measured on Day  3 from the skin biopsy  by 1) 
quantitative CFU plating, 2) the numbers of genomes of BCG by [CONTACT_349817],  and if sufficient material is available, by 3)  additional assays may be performed to assess the 
integrity of t he immune system . 
 Blood samples  (via venipuncture)  
• Serum will be collected on  Days : 0, 1, 2, 3, 4, 8±1, 15±1, 28±1 56± 2, and 84± 3, scheduled 
visits will be collected for inflammatory markers (IL -2, IL-4, IL-5, IL-8, IL-10, INFγ, 1l -
12p70, 1l -17A, IL -1, IL-6 and TNF -α levels) using Cytokine BeadArray, and clinical testing 
for acute phase reactants (ESR and CRP).  
 
Kublin_ Phase I human B CG challenge  trial                    Page 21 of 41    
Version: 03/29/2022  
 • Blood will be collected for ELISPOT /ICS and additional assays to assess the integrity of 
the immune system  on Days : 0, 8±1, 28±1, 56±2, 84±3, and 114±1.  Whole blood will be 
collected for RNA seq studies on Days: 0, 1, 2, 3,  4, 8±1, 15±1, 28±1, 56± 2, and 84±3.  
Plasma obtained from the density gradients used to purify PBMCs will be collected and 
frozen on Days : 0, 1, 8±1, 15±1, 28±1, 56±2, 84±3 , and 114 ±1.  Anticoagulated whole 
blood will be collected for dendritic cell (DC), monocyte and natural killer (NK) cell 
assays  on Days : 1, 4, 8±1, 15±1, 28±1, 56± 2, and 114± 1.  
10.7 Photographs  
 
Photographs of the ID challenge site will be taken at each follow -up visit after Tice® BCG administration 
starting on Day 4 through Day 56± 2.  If the participant  has any abnormality and does n ot have a well -
healed scar, or the site is open and/or draining, photographs will continue once /week from the day the 
abnormality was identified until it has resolved .  All subjects will have a final photograph of the ID 
challenge site on Day 114±[ADDRESS_434885] will be performed  and/or accessed on Days : 98±1, 100 ±1, 112± 1 and 114±[ADDRESS_434886] results is positive, defined as ≥ [ADDRESS_434887] a QuantiFERON® -TB Gold Test performed to determine TB infection or BCG immunity.  
 
10.9 Memory Aid eCRF Device and AE/SAE Recording Training  
 
Participants will be instructed on how to use the initial and on -going subject memory aids eCRF device 
and how to measure and record AEs/SAEs , concomitant medication and other health status information . 
11.0 STUDY SCHEDULE  
 
11.1 Participant Procedures Sched ule 
See Appendix B  
 
11.2 Clinic Visit Schedule 
 
Screening visit:  A single visit between Days -42 and -1 (visit 1)  
• Informed Consent  
• Review medical history ,  
• Review concomitant medications, 
• Collect vital signs (oral temperature, pulse, blood pressure) ,  
• Collect height and weight (to calculate BMI) , 
• General examination , 
• Collect urine for dipstick for protein < 1 and negative for glucose  and chlamydia/gonorrhea test,  
 
Kublin_ Phase I human B CG challenge  trial                    Page 22 of 41    
Version: 03/29/2022  
 • Blood draw  (29mls (6 teaspoons ( tsp)) for testing HIV, hepatitis B surface antigen, antibody to 
hepatitis C virus,  syphilis  and QuantiFERON® -TB Gold Test.  Results of these screening tests must be 
negative , 
• Pregnancy tests for females of childbearing potential (must be negative for eligibility) . 
o Serum pregnancy test  at screening,  
o Urine pregnancy test within 24 hours prior to enrollment  and receipt of Tice® BCG and INH.  
Day 0 (clinic visit  2) 
• Administration of BCG 2x106 cfu Tice® BCG: one intradermal injection in the deltoid region , 
* Following administration of Tice® BCG, intradermal (ID) site reactions will be assessed for at least 
30 minutes .  
• Blood draw  via venipuncture for immunogenicity and mycobacteria assays : 114.5mls (8 tbs) , 
• Participants will be instructed on how to use the initial and on -going subject memory aids eCRF 
device and how to measure and record AEs/SAEs prior to discharge from the clinic ,  
• In addition, subjects will be instructed to keep the ID challenge site covered with a dressing (sterile 
gauze, etc.) and all dressings that have been used to cover  the ID challenge site will be collected in 
sealable clear plastic bags. These materials will be collected from subjects at follow -up visits and 
properly disposed of as biohazard waste. Subjects will also be counseled to avoid any direct contact [CONTACT_349818] e with an immunosuppressed person.  
Day 1 (c linic visit 3), Day 2 (clinic visit 4) , and Day 3 (clinic visit 5)  
• Assess ID challenge site , 
• Day 3 (clinic visit 5) only: skin biopsy,  
• Review health status and AEs/SAEs that were recorded on the memory aid eCRF device ,  
• Blood draws via venipuncture  for immunogenicity and mycobacteria assays :  
o Day 1: 6.5mls (1.5 tsp) ,  
o Day 2: 6.5mls (1.5 tsp),  
o Day 3: 6.5mls (1.5 tsp) , 
• Subjects will be reminded to  record  self- assessments on their redcap survey : 
o Oral temperature (optional)   
o Solicited local and systemic reactions  recorded Days 1 -114,  
o Unsolicited AEs/SAEs  recorded Days 1 -114, 
o Concomitant medications  recorded Days 1 -114. 
• Collection of used dressing/gauze . 
Days  4 (clinic visit 6) , 5 (clinic visit 7) , 6 (clinic visit 8), 8±1 (clinic visit 9), 15±1  (clinic visit  10), and 28  ± 1 
(clinic visit 11)  
• INH dosing days 4, 5, and 6 only: For the 5 participants assigned  to Group 1, they will take INH: oral 
tablets of either three 100mg tablets (total 300mg) or one 300mg table t for [ADDRESS_434888] BCG dosing , 
• Days  8±1 (clinic visit 9)  and 15±1 (clinic visit 10)  only: Repeat skin biopsy,  
• Assess ID challenge site,  
• Review health s tatus and AEs/SAEs that were recorded on the memory aid eCRF device,  
• Review concomitant medications,  
• Assess for lymphadenopathy if indicated based on review of interim medical history and clinical 
assessment,  
 
Kublin_ Phase I human B CG challenge  trial                    Page 23 of 41    
Version: 03/29/2022  
 • Targeted physical exam  and clinical assessment  may be performed if indicated based on review of 
interim medical history, reactogenicity (as applicable) , 
• Blood draws via venipuncture for immunogenicity and mycobacteria assays :  
o Day 4: 6.5mls (1.5 tsp),  
o Day 8±1 : 74.5mls (5 tables poons ( tbs)), 
o Day 15±1 : 56.5mls (4 tbs),  
Day 28±1: 94.5mls ( 6 tbs),  
• Collect used dressing/gauze,  
• Photograph of ID challenge site.  
Days 16- 114±1  
• On-going participant self- evaluations that will be recorded on their memory aid eCRF device for 
pain, tenderness and drainage. Participants can record their temperature if taken.   
 
Days  56±2 (clinic visit 1 2) and 84±3 (clinic visit  13) 
• Day 56±2 (clinic visit 1 2) only: Repeat skin biopsy  
• Assess ID challenge site  (if an abnormal BCG injection site is identified see Abnormal BCG Injection 
Site Procedures in section 11.3),  
• Review health status and AEs/SAEs that were recorded on the memory aid eCRF device,  
• Review concomitant medications,  
• Assessments for lymphadenopathy if indicated based on review of interim medical history and 
clinical assessment,  
• Targeted general exam and clinical assessment may be performed if indicated based on review of 
interim medical history, reactogenicity (as applicable) , 
• Blood draws  via venipuncture for immunogenicity and mycobacteria assays : 
o Day 56±2: 94.5mls (6 tbs) 
o Day 84±3: 94.5mls (6 tbs) 
• Collect used dressing/gauze,  
• Photograph of ID challenge site . 
Day 98±1 (clinic visit  14) 
• Assess ID challenge site,  
• Review health status and AEs/SAEs that were recorded on the memory aid eCRF device,  
• Review concomitant medications,  
• Blood draw  via venipuncture for diagnostic  assays: 4mls (1 tsp ), 
• [COMPANY_003] skin test. 
Day 100±1 (clinic visit  15) 
• Assess ID challenge site , 
• Review health status and AEs/SAEs that were recorded on the memory aid eCRF device,  
• Review concomitant medications,  
• [COMPANY_003] skin test assessment . 
*Day 120/134: If the first [COMPANY_003] skin test result is negative, then the s econd [COMPANY_003] skin test will be 
performed [ADDRESS_434889] results is positive, defined as ≥ 10 
 
Kublin_ Phase I human B CG challenge  trial                    Page 24 of 41    
Version: 03/29/[ADDRESS_434890] a QuantiFERON® -TB Gold Test performed to 
determine TB infection or BCG immun ity. 
Days 112±1  (clinic visit 1 6) 
• Assess ID challenge site,  
• Review health status and AEs/SAEs that were recorded on the memory aid eCRF device,  
• Review concomitant medications,  
• Blood draw via venipuncture for diagnostic assays: 4mls (1 tsp),  
• [COMPANY_003] skin test.  
Day 114±1 (clinic visit  17) End of Study  
• General e xam,  
• Assess ID challenge site , 
• Review health status and AEs/SAEs that were recorded on the memory aid eCRF device,  
• Review concomitant medications,  
• Blood draw via venipuncture for immunogenicity and humoral  assays : 138mls ( 9.5 tbs),  
• Photograph of ID challenge site,  
• [COMPANY_003] skin test assessment , 
• Participant s returns memory aid eCRF device s. 
 
11.3 Abnormal BCG Injection Site Procedures  
 
The BCG injection site evaluations are  scheduled from Day 0 to 84±3. However, s igns of an abnormal 
injection site may present around Day 28. If an injection site does not have a well healed scar, or has an 
open and draining ulcer , then th e subject will be aske d to return to the clinic twice per/week from the 
time the abnormality is identified until it has resolved.  At each of these visits t he following evaluations  
will be completed : assessments of the ID challenge site, assessments for lymphadenopathy if indicated 
based on review of interim medical history and clinical assessment, as well as review AEs/SAEs, concomitant medications, and health status, and collect and dispose of returned biohazard materials.  
Photographs will be taken once  per/week from the day of the abnormal assessment until it has resolved .
  
 
11.[ADDRESS_434891] 7 days, but < 30 days, after the dose of BCG.  
Procedures to be performed on visits 1 4-17 : see above  in section 11.2 Clinic Visit Schedule . 
12.0 LABORATORY TESTING AND ASSAY SCHEDULE  
 See Appendix A  for Laboratory Procedures Table . 
 
Kublin_ Phase I human B CG challenge  trial                    Page 25 of 41    
Version: 03/29/2022  
  
 
13.0 SAFETY MONITORING COMMITTEE  
 
A Saf ety Monitoring Committee (SMC) will be convened periodically by [CONTACT_349819], which may include solicited and unsolicited AEs/SAEs, concomitant medications, clinical laboratory values 
and any physical examinations. Interim statistical reports may be generated as deemed necessary. The SMC may receive data in aggregate and presented by [CONTACT_19313]. As an outcome of each review, the SMC will make a recomme ndation at that time as to the advisability of proceeding with Tice® BCG administration, and to 
continue, modify or terminate the study.  
13.1 Primary Endpoint  
• The rate of AE’s/SAE’s related to Tice® BCG administration reported at any point during the 
study , 
• Sum mary of the distribution of viable BCG bacteria from intradermal challenge sites at 4 
time points (approximately 3 days and 1, 2, and 4 weeks  following Tice® BCG 
administration), as detected by [CONTACT_349820]. The distribution will be summarized in terms of its central tendency (mean or GM) and its precision represented by 
[CONTACT_209118] 95% confidence interval.  
13.2 Secondary Endpoint  
• Quantitative bacterial 16S r ibosomal DNA PCR , 
• Microbial viability testing pre -ribosomal RNA RT -PCR, 
• Humoral and cellular immune responses after BCG immunization . 
 
 
14.[ADDRESS_434892] may be withdrawn from the study for the following reasons:  
• The subject withdraws consent ,  
• The subject develops a medical disease or condition, or any new clinical findings for which 
continued participation, in the opi[INVESTIGATOR_29352] -
investigator, would compromise the safety of the subject, would interfere with the subject's 
successful completion of this study, or would inte rfere with the evaluation of responses , 
• The subject fails to comply with the scheduled study visits ,  
• The study is terminated , 
• Any reason that, in the opi[INVESTIGATOR_871], precludes the subject's continued 
participation in the study ,  
• The subject becomes pregnant . 
 
Kublin_ Phase I human B CG challenge  trial                    Page 26 of 41    
Version: 03/29/2022  
  
15.0 ASSESSMENT OF SAFETY  
15.1 Specification of Safety Parameters  
 
Safety will be assessed by [CONTACT_12218]:  
1. Tice® BCG- related serious adverse events occurring throughout the course of the study , 
2. Solicited Adverse Events – reactogenicity events following Tice® BCG administration:  
a) Local reactions including pain, tenderness, erythema/redness, and induration/swelling at 
the injection site.  
b) Systemic reactions including fever, chills, malaise/fatigue, headache, night sweats, nausea, 
vomiting, diarrhea, rhinorrhea, cough, and wheezing or shortness of breath.  
3. Lesion characterized as erythematous macule, non -erythematous papule, erythematous papule, 
vesicle, pustule, ulcer, eschar/crust, healed, scar, or keloid , 
4. Lymphadenopa thy,  
5. Clinical safety laboratory adverse events to include WBC, hemoglobin, and platelet count, creatinine and ALT (SGPT ), 
6. Unsolicited Adverse Events . 
a) Non -serious adverse events occurring in the 56 days following Tice® BCG administration.  
15.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters  
 
15.2.1  Adverse Events  
Adverse Event (AE):  
International Conference on Harmonisation (ICH) E6 defines an AE as  any untoward medical 
occurrence in a patient or clinical investigation subject administered a pharmaceutical product 
regardless of its causal relationship to the study treatment. An AE can  therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding),  symptom, or 
disease temporally associated with the use of a medicinal (investigational) product.  The 
occurrence of an AE may come to the  attention of study personnel during study visits and  
interviews of a study treatment recipi[INVESTIGATOR_12189], or upon review by a study  
monitor.  
 
All AEs, inc luding local and systemic reactions, not meeting the protocol -defined criteria for 
serious adverse events (SAEs) should be captured on the appropriate data collection form and  
eCRF. Information to be collected for unsolicited AEs includes event description , date of onset,  
study clinician’s assessment of severity and relationship to study product and alternate etiology  
(if not related to study product) (assessed only by [CONTACT_8703] a diagnosis ), date of resolution/stabilizat ion of the event, seriousness and  
outcome. All AEs occurring while on study will be documented appropriately regardless of  
relationship. All AEs will be followed to adequate resolution.  
 
Any medical condition that is present at the time that the subject is  screened should be  
considered as baseline and not reported as an AE. However, if the severity of any pre -existing  
medical condition increases at any time during the study, it should be recorded as an AE.  
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 27 of 41    
Version: 03/29/[ADDRESS_434893] (see  
definitions below). Adverse events characterized as intermittent require documentation of 
onset  and duration of each epi[INVESTIGATOR_1865]. The start and stop date of each reported AE will be 
recorded on  the appropriate data collect ion form and eCRF.  
 
Severity of Event:   
All AEs will be assessed by [CONTACT_16541] [INVESTIGATOR_29353] -investigator  using 
the protocol -defined grading system (Section 15.2.2 -15.2.3). For events not included in  the 
protocol defined grading system, the following guidelines will be used to quantify severity: 
• Mild (Grade 1) : events require minimal or no treatment and do not interfere 
with the patient’s daily activities.  
• Moderate (Grade 2) : events result in a low level of inconvenience o r concern 
with the therapeutic measures. Moderate events may cause some interference 
with functioning and daily activities.  
• Severe (Grade 3) : events interrupt a patient’s usual daily activity and may 
require systemic drug therapy or other treatment. Severe  events are usually 
incapacitating.  
Relationship to Study Products:  
The study clinician’s assessment of the relationship of an  AE’s relationship to study product is 
part of the documentation process, but it is not a factor in  determining what is or is not  
reported in the study. If there is any doubt as to whether a clinical observation is an AE, the 
event should be reported. All AEs must have their relationship to  study product assessed using 
the following terms: related or not related. In a clinical trial, the  study product must always be 
suspect. To help assess, the following guidelines are used:  
• Related : There is a reasonable possibility that the study product caused the 
adverse event. Reasonable possibility means that there is evidence to suggest a caus al relationship between the study product and the adverse event.  
• Not Related : There is not a reasonable possibility that the administration of the 
study product caused the event.  
15.2.2  Reactogenicity  
 
Reactogenicity events are AEs that are known to occur with Tice® BCG. Reactogenicity events  
will be analyzed according to the following grading scales:  
 
Table 1: Reactogenicity Events Grading Scales  
 
Local Reaction  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Pain – experienced 
without touching 
the injection site  Subject is aware of pain 
but it does not interfere with daily activity and no 
pain medication is taken  Subject is aware of pain; 
there is interference with daily activity or it 
requires use of pain 
medication  Subject is aware of pain 
and it prevents daily 
activity  
Tenderness – hurts 
only when injection 
site is touched  The area immediately 
surrounding the injection site hurts only when touched and it 
does not The area immediately 
surrounding the injection site hurts when touched and it interferes 
with daily activity  The area immediately 
surrounding the injection site hurts when touched and it prevents 
daily activity  
 
Kublin_ Phase I human B CG challenge  trial                    Page 28 of 41    
Version: 03/29/2022  
 interfere with daily 
activity  
Erythema/Redness*  Does not interfere with 
activity  Interferes with activity  Prevents daily activity  
Induration/ 
Swelling*  Does not interfere with 
activity  Interferes with activity  Prevents daily activity  
Drainage  Continuous use of 
bandage cover or less 
than 2, 2x2 gauze 
pads/day  Needs 2 -4, 2x2 gau ze 
pads/day  Needs more than 4, 2x2 
gauze pads/day  
* Will be also measured in mm but size will not be used as halting criteria.  
 
Erythema/redness, induration/swelling and lesion as analyzed by [CONTACT_349821]:  
 
Table 2: Erythema/Redness, Induration/Swelling and Lesion Measurement Grading Scales  
 
 Small  Medium  Large  
Total 
Erythema/Redness*  <20 mm  20-50 mm  >50 mm  
Maximum Diameter 
of 
Induration/Swelling*  <20 mm  20-50 mm  >50 mm  
Central Lesion  <10 mm  10-30 mm  >30 mm  
* Measurement will not be used as halting criteria  
 
 
Table 3: Reactogenicity Events Grading Scales (Continued)  
 
Systemic 
(Subjective)  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  
Chills  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
Malaise/Fatigue  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
Headache  No interference with 
activity  Some interference with 
activ ity Significant interference, 
prevents daily activity  
Night Sweats  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
Nausea  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
Vomiting  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
Diarrhea  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
Rhinorrhea  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
Cough  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
 
Kublin_ Phase I human B CG challenge  trial                    Page 29 of 41    
Version: 03/29/2022  
 Wheezing/Shortness 
of Breath  No interference with 
activity  Some interference with 
activity  Significant interference, 
prevents daily activity  
 
Vital signs# (oral temperature, pulse and blood pressure) will be analyzed according to the following 
grading scales:  
 
 
Table 4: Vital Signs Grading Scales  
 
Systemic (Quantitative) Mild (Grade 1) Moderate (Grade 2) Severe (Grade 3) 
Fever* 38.0 -38.4°C  
100.4 -101.1°F 38.5 -38.9°C  
101.2 -102°F ≥39°C  
≥102.1°F 
Tachycardia - beats per 
minute† 101-115 116-130 >130 
Bradycardia - beats per 
minute 45-49 40-44 <40 
Hypertension (systolic) 
mm Hg 141-150 151-155 >155 
Hypertension (diastolic) 
mm Hg 91-95 96-100 >100 
Hypotension (systolic) 
mm Hg 85-89 80-84 <80 
Hypotension (diastolic) 
mm Hg 45-49 40-44 <40 
# Vital Signs assessed at Day 1 will be considered as baseline.  
* Oral temperature, no recent hot or cold beverages or smoking. Note: A fever can be considered not related to the study  product if an alternative etiology can be documented and it is confirmed to be not 
related to the study product by [CONTACT_349822].  
† Subject at rest.  
 
15.2.3  Additional Adverse Event Characterization and Severity Grading 
 
Lesions at the ID challenge  site will be characterized by [CONTACT_349823]: 
1. Erythematous Macule: flat red spot . 
2. Non -Erythematous Papule: a small, circumscribed, non -erythematous, palpable elevation  in 
the skin . 
3. Erythematous Papule: a small, circumscribed, erythematous, palpable elevation in the  skin.  
4. Vesicle: clear fluid filled papule.  
5. Pustule: cloudy, purulent fluid filled papule.  
6. Ulcer: an open lesion on the surface of the skin caused by [CONTACT_349824], often  
attended by [CONTACT_349825].  
7. Eschar/Crust: a lesion with an erythematous base and a central scab (a coagulation  product 
of blood, serum, pus, or a combination of two or more of these).  
8. Healed: previously observed lesion that has dried up without any persistent induratio n, 
ulcer, or eschar. Redness under an area of previous eschar formation seen after the  eschar 
 
Kublin_ Phase I human B CG challenge  trial                    Page 30 of 41    
Version: 03/29/2022  
 has fallen off during the healing process would not be considered active erythema,  but 
instead would be considered evidence of a healed lesion.  
9. Scar: replacement of normal skin with fibrous tissue (other than keloid formation).  
10. Keloid: nodular scar.  
Severity Grading for Lymphadenopathy  
The site principal investigator [INVESTIGATOR_29353] -investigator licensed to make medical 
diagnoses will assess the severity of axillary, cervical, and  epi[INVESTIGATOR_349792]:  
 
Table 5: Severity Grading for Lymphadenopathy  
 
Grade  Definition  
Grade 0 (none)  No palpable nodes, or all nodes < 1 cm (pea -sized), 
mobile, and nontender.  
Grade 1 (mild)  At least one node ≥ 1 cm (pea -sized) but < 2.5 cm 
(cherry -sized), but mobile and non - tender or 
tender only with firm pressure.  
Grade 2 (moderate)  At least one node ≥ 2.5 cm (cherry -sized) or tender 
to light touch or spontaneously reported as 
painful, but not causing significant limitation of 
normal everyday activities.  
 
Grade 3 (severe)  At least one node that is tender to light touch or 
spontaneously reported as painful AND causing significant limitation of normal everyday activities. Any one of palpable fluctuance or heat, fixation to 
underlying tissues, or visible erythema.  
  Severity Grading for Clinical Safety Laboratory Adverse Events  
 
Table 6: Severity Grading for Clinical Safety Laboratory Adverse Events - Hematology  
Hematology  Mild  
(Grade 1)  Moderate  
 (Grade 2)  Severe  
(Grade 3)  
WBC (Increase) 103/UL 10.6 – 15.0  15.1 – 20.0  >20.0  
WBC (Decrease) 103/UL 2.5 – 3.9 1.5 – 2.4 <1.5  
HgB (Female) g/dL  10.1 – 11.4  8.5 – 10 <8.5  
HgB (Male) g/dL  11.0 – 12.4  9.5 – 10.9  <9.5  
Platelets (Decrease) 103/UL 125 – 139 100 – 124 <100  
 
Table 7: Severity Grading for Clinical Safety Laboratory Adverse Events - Chemistries  
 
Chemistries  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  
Creatinine mg/dL  1.31 – 1.70  1.71 – 2.00  >2.00  
ALT (SGPT) (Female) IU/L  41 – 100 101 – 200 >200  
 
Kublin_ Phase I human B CG challenge  trial                    Page 31 of 41    
Version: 03/29/2022  
 ALT (SGPT) (Male) IU/L  56 – 138 139 – 275 >275  
 
15.2.4  Serious Adverse Events  
 
Serious Adverse Event (SAE):   
An adverse event or suspected adverse reaction is considered  “serious” if, in the view of either 
the site principal investigator [INVESTIGATOR_10157], it results in any of the  following outcomes:  
 
• Death . 
• A life -threatening adverse event*. 
• Inpatient hospi[INVESTIGATOR_1081] . 
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct  normal life functions, or  
• A congenital anomaly or birth defect.  
• Important medical events that may not result in death, be life threatening, or 
require  hospi[INVESTIGATOR_11298], may be considered serious when, based upon appropriate 
medical  judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition. Examples of such medical  events include allergic bronchospasm requiring 
intensive  treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do  not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency or drug abuse.  
 
* Life-threatening adverse event. An adverse event is considered “life-
threatening” if, in the  view of either the investigator or sponsor, its occurrence 
places the patient or subject at  immediate risk of death. It does not include an 
adverse event that, had  it occurred in a more  severe form, might have caused 
death.  
 
All SAEs will be:  
• Assessed for severity and relationship to study product and alternate etiology (if not  
related to study product) by a licensed study physician.  
• Recorded on the appropriate SAE form and eCRF. 
• Followed through resolution or stabilization by a study clinician licensed to make  
medical diagnoses.  
• Reviewed and evaluated by [CONTACT_349826]. Related and unexpected SAEs will 
also be reviewed by [CONTACT_1201].  
 
15.2.[ADDRESS_434894] Values or  Abnormal Clinical 
Findings  
 
The site principal investigator [INVESTIGATOR_349793]/SAEs that are observed or  
reported during the study, regardless of their relationship to study product. AEs/SAEs, abnormal  
laboratory test values or abnormal clinical findings will be documented, reported and followed  
appropriately. Adverse events will be assessed through approximately 8 weeks following Tice®  
BCG administration. Serious adverse events will be assessed for the study duration.  
 
15.3 Reporting Procedures  
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 32 of 41    
Version: 03/29/2022  
 • Document AEs from Visit 02 (Day 0) through Visit 10 (Day 56±2). 
• Document SAEs from Visit 02 (Day 0) through Visit 15 (Day 114±1). 
 
16.0 DATA AND SAFETY MONITORING PLAN  
 
The Data Safety Monitoring Plan for this study includes the Safety Monitoring Committee (SMC) noted in Section 
13.[ADDRESS_434895] (IRB). The IRB 
reviews the study progress and safety i nformation to assess continued acceptability of the risk -benefit ratio for 
human subjects.   Approval of committees as applicable is necessary to continue the study.  The study 
investigators will monitor for adverse events and will refer participants for local medical care if necessary.  
 
 
17.0 DATA MANAGEMENT/CONFIDENTIALITY  
 
The site principal investigator [INVESTIGATOR_307589], completeness, legibility, and timeliness of the data reported.  
 
Data collection forms will be derived from the eCRF and provided by [CONTACT_349827].  All data collection forms should be completed in a neat, legible manner to ensure accurate interpretat ion of data.  Black or blue ink is required to ensure clarity of reproduced 
copi[INVESTIGATOR_014].  When making a change or correction, cross out the original entry with a single line and initial and date the change.  Do not erase, overwrite, or use correction fluid or t ape on the original.   
 Data reported in the eCRF should be consistent with all source documents or the discrepancies should be explained.  
 
17.[ADDRESS_434896] maintain complete and accurate documentation for the study.  
 The Seattle MCTC will be responsible for data management, quality review, analysis, an d reporting of 
the study data.   
17.2 Data Capture Methods  
 
Clinical data (including AE/SAEs, concomitant medications, physical assessments, and reactogenicity data) will be entered into the Seattle MCTC’s Clinical Conductor
® web -based 21 CFR Part 11 -compliant 
Clinical Trial Management System . Clinical data will primarily be entered directly from the data 
collection forms.    
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 33 of 41    
Version: 03/29/2022  
  
17.3 Types of Data  
 
Data for this study will include safety, laboratory (clinical and research), and outcome measures (e.g., 
reactogenicity and immunogenicity).  
17.[ADDRESS_434897] be retained b y the 
investigator indefinitely that is the policy of Fred Hutch .  
 The principal investigators will ensure that this trial is conducted in full conformity with principles of the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research 
(National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research [April 18, 1979]) and codified in [ADDRESS_434898] access to all protocol- related source data/source documents, 
and reports for the purpose of monitoring and auditing and inspection by [CONTACT_3482]. The Principal Investigator [INVESTIGATOR_349794]. All personnel involved in the conduct of this study have completed Human Subjects Protection and ICH GCP Training. The study staff will implement quality control procedures beginning with the data entry system; database quality control che cks will be 
implemented. Any missing data or data anomalies will be updated for clarification and resolution.  
 
 
18.0 STATISTICAL CONSIDERATIONS   
 
18.1 Sample Size and Power  for Outcome Measures  
 
The study is designed to demonstrate the safety, tolerability and feasi bility of using intradermal BCG as a model 
for the evaluation of TB drugs. With 5 participants in each arm and a low number of AE/SAEs expected, the study 
is not powered for direct comparison of the two study groups. Instead, reactogenicity, AEs and SAEs w ill be 
presented with descriptive statistics summarizing each group. Interpretation of differences will rely heavily upon 
clinical judgment. In the rare event that there is a high frequency safety event of at least 25% in one of the groups there will be a 76% chance of observing at least one event and a 37% chance of observing 2 events in the 
relevant group. All participants are expected to provide safety data
. 
 
True event 
rate (%)  Pr(0/ 5) Pr(≥1/5) Pr(≥2/5) 
5 0.77  0.23  0.02  
 
Kublin_ Phase I human B CG challenge  trial                    Page 34 of 41    
Version: 03/29/[ADDRESS_434899] a difference in the number of participants with detectable 
BCG either by [CONTACT_349828]. The plot below shows that a low rate of BCG detection in the treatment arm (<0.05) and a high rate of detection in the control  arm (>0.95) there will be > 90% power to detect a difference 
between the groups (Fisher’s exact test, two -sided α=0.05). Power will be diminished if the actual detection 
rates are shifted toward 0.[ADDRESS_434900] ive. 
 
 
 
Descriptive statistical analyses will be conducted with the data generated from the Secondary Endpoints. The analyses will generate hypotheses to be tested in future studies.  
 
18.2 Randomization  
The participants assignment to either Group 1 and 2 will be computer generated.  
18.3 Ethnic and Gender Distribution Chart  
The target population reflects the Seattle King County community. Projected Target Accrual  
 
ETHNIC AND GENDER DISTRIBUTION CHART  
 
TARGETED / PLANNED ENROLLMENT: Number of Subjects  
Ethnic Category   
Sex / Gender  
 
Females  Males  Total  
Hispanic or Latino  0 0 0 

 
Kublin_ Phase I human B CG challenge  trial                    Page 35 of 41    
Version: 03/29/2022  
 Not Hispanic or Latino  5 5 10 
Ethnic Category Total of All Subjects*  5 5 10 
 
Racial Categories  
  
American Indian / Alaska Native  0 0 0 
Asian  1 1 2 
Native Hawaiian or Other Pacific Islander  0 0 0 
Black or African American  0 0 0 
White  4 4 8 
More Than One Race  0 0 0 
Racial Categories: Total of All Subjects*  5 5 10 
19.0 ETHICS/PROTECTION OF HUMAN SUBJECTS 
 
19.[ADDRESS_434901]  
 
The participating institution will provide for the review and approval of this protocol and the associated 
informed consent documents and recruitment material to the Fred Hutch IRB, registered with OHRP.  
Any amendments to the protocol or consent materials  will also be IRB approved before they are placed 
into use.  
 
19.2 Informed Consent Process  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continuing throughout the individual’s study participa tion.  Extensive discussion of risks and 
possible benefits of participation in this study will be provided to the subjects and their families.  Consent forms describing in detail the study procedures and risks are given to the subject and written documenta tion of informed consent is required prior to enrolling in the study.  Consent forms will be IRB 
approved and the subject will be asked to read and review the document. Upon reviewing the document, the investigator will explain the research study to the su bject and answer any questions that 
may arise.  The subjects will sign the informed consent document prior to being enrolled in the study.  The subjects should have the opportunity to discuss the study with their surrogates or think about it prior to agree ing to participate.  The subjects may withdraw consent at any time throughout the course 
of the study.  A copy of the informed consent document will be given to the subjects for their records.  The rights and welfare of the subjects will be protected by [CONTACT_349829].  
 
19.3 Exclusion of Minors  
 
Minors  under the age of 1 8 are excluded from this study as  there are no benefits for participation  in the 
stud y.  
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 36 of 41    
Version: 03/29/[ADDRESS_434902] -protected servers at 
sponsor site. After the study is completed, the coded  data may be used by [CONTACT_349830]. Permission for use of coded, deidentified data collected for the study for 
future research will be included in the informed consen t.  
 With the participant’s approval and as approved by [CONTACT_349831], de -identified biological samples will 
be stored as part of a repository so it can later could be used to research the role of BCG  in human 
challenge models and other inflammatory processes. The repository will also be provided with a code -
link that will allow linking the biological specimens with the phenotypic  data from each participant, 
maintaining the blinding of the identity of the participant.  
 During the conduct of the study, an individual participant can choose to withdraw consent to have 
biological specimens stored for future research. However, withdrawal of consent with regard to biological sample storage may not be possible after the study is completed.  
20.[ADDRESS_434903] submitted for them to the National Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) an electronic version of their final, peer-reviewed manuscripts upon acce ptance for publication, to be made publicly available no later than [ADDRESS_434904] applied for certification of delayed posting.  
21.0  REFERENCES  
 
1. World Health Organization (WHO). ([ADDRESS_434905] 17). Global tuberculosis report 2019. Retrieved from 
https://www.who.int/tb/publications/global_report/en  
 
Kublin_ Phase I human B CG challenge  trial                    Page 37 of 41    
Version: 03/29/2022  
 2. Kyu HH, Maddison ER, Henry NJ, Ledesma JR, Wiens KE, … Murray CJL. Global, regional, and national 
burden of tuberculosis, 1990 -2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 
[ADDRESS_434906] Dis. 2018 Dec;18(12):[ADDRESS_434907] Achieving Global Targets - 2017.  MMWR Morb Mortal Wkly Rep. 2019 Mar 
22;68(11):263- 266. PMID 30897077 . 
4. Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M . Global tuberculosis targets and 
milestones set for 2016 -2035: definition and rationale. Int J Tuberc Lung Dis. 2018 Jul 1;22(7):723 -730. 
PMID 29914597. 
5. Sable SB, Posey JE, Scriba T J. Tuberculosis Vaccine Development: Progress in Clinical Evaluation.  Clin 
Microbiol Rev. [ADDRESS_434908] 30;33, Print 2019 Dec 18.  PMID 31666281 . 
6.  Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, …Tait DR. Phase 2b Controlled 
Trial of M72/AS01E Vaccine to Prevent Tuberculosis.  N Engl J Med. [ADDRESS_434909] 25;379(17):1621- 1634. 
PMID 30280651. 
7. Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, … Self SG . Tuberculosis vaccines and prevention 
of infection. Microbiol Mol Biol Rev. 2014 Dec;78(4):650- 71. PMID 25428938.  
8. Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F,… C- 040-404 Study Team . Prevention of M. 
tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.  N Engl J Med. 2018 Jul 12;379(2):138-
149.  PMID 29996082.  
9. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, …Savic RM . Publisher Correction: A patient -level 
pooled analysis of treatment -shortening regimens for drug- susceptible pulmonary tuberculosis.  Nat 
Med. 2019 Jan;25(1):190.  PMID 30429542.  
10. Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development pi[INVESTIGATOR_349795]. Cold Spring Harb Perspect Med. 2015 Jan 29;5(6) . PMC  4448709.  
11. Jindani A, Aber VR, Edwards EA. The early bactericidal activity of drugs in patients with pulmonary 
tuberculosis.  Am Rev Respir Dis. 1980 Jun;121(6):939- 49. PMID 6774638.  
12. Bonnett LJ, Ken -Dror G, Koh GCKW , Davies GR . Comparing the Efficacy of Drug Regim ens for Pulmonary 
Tuberculosis: Meta -analysis of Endpoints in Early -Phase Clinical Trials.  Clin Infect Dis. 2017 Jul 
1;65(1):46- 54. PMID 28402396.  
13. Field SK . Bedaquiline for the treatment of multidrug- resistant tuberculosis: great promise or 
disappointment?  Ther Adv Chronic Dis. 2015 Jul;6(4):170 -84. PMID 26137207.  
14. Minassian AM1, Ronan EO, Poyntz H, McShane H. Preclinical development of an in vivo BCG challenge 
model for testing candidate TB vaccine efficacy.  PLoS One. 2011;6(5): Epub  2011 May 24.  PMID 
21629699.  
15. Harris SA, White A, Stockdale L , Tanner R, Sibley L ,…,Sharpe S . Development of a non -human primate 
BCG infection model for the evaluation of candidate tuberculosis vaccines.  Tuberculosis (Edinb). 2018 
Jan;108:99- 105.  PMID [ZIP_CODE] 335.  
16. Tyagi S, Ammerman NC, Li SY , Adamson J, Converse PJ, … Grosset JH . Clofazimine shortens the duration 
of the first -line treatment regimen for experimental chemotherapy of tuberculosis.  Proc Natl Acad Sci U 
S A. 2015 Jan 20;112(3):[ADDRESS_434910] 1;200(7):1136 -43. PMID 19686043.  
 
Kublin_ Phase I human B CG challenge  trial                    Page 38 of 41    
Version: 03/29/2022  
 18. Sridevi JP, Anantaraju HS, Kulkarni P , Yogeeswari P, Sriram D . Optimization and validation of 
Mycobacterium marinum -induced adult zebrafish model for evaluation of oral anti- tuberculosis drugs.  
Int J Mycobacteriol. 2014 Dec ;3(4):259 -67. PMID 26786625.  
19. Lin PL1, Coleman T2, Carney JP , Lopresti BJ, Tomko J, …Flynn JL . Radiologic Responses in Cynomolgus 
Macaques for Assessing Tuberculosis Chemotherapy Regimens.  Antimicrob Agents Chemother. 2013 
Sep;57(9):4237 -4244. PMID 23796926.  
20. Dhillon J, Mitchison DA.  Influence of BCG-induced immunity on the bactericidal activity of isoniazid and 
rifampi[INVESTIGATOR_349796] -pig. Br J Exp Pathol. 1989 
Feb;70(1):[ADDRESS_434911] ML , Orme EA, Henao -Tamayo M ,…Basaraba RJ. Drug treatment combined 
with BCG vaccination reduces disease reactivation in guinea pi[INVESTIGATOR_349797].  Vaccine. 2012 Feb 21;30(9):1572- 82. PMID 22244979 . 
22. Akselband Y, Cabral C, Shapi[INVESTIGATOR_349798], McGrath P . Rapid mycobacteria drug susceptibility testing using Gel 
Microdrop (GMD) Growth Assay and flow cytometry.  J Microbiol Methods. 2005 Aug;62(2):181- 97. 
PMID 16009276. 
23. Weigel KM, Jones KL, Do JS, Melton Witt J, Chung JH, Valcke C, Cangelosi GA . Molecular viability testing 
of bacterial pathogens from a complex human sample matrix.  PLoS One. 2013;8(1) . PMID 23365682. 
24. Do JS, Weigel KM, Meschke JS, Cangelosi GA.  Biosynthetic enhancement of the detection of bacteria by 
[CONTACT_293715]. PLoS One. 2014 Jan 17;9(1): eCollection 2014.  PMID [ADDRESS_434912] Dis. 2012 Apr 
1;205(7):1035 -42. PMID 22396610. 
26. Harris SA, Meyer J, Satti I, Marsay L, Poulton ID, … McShane H.  Evaluation of a human BCG challenge 
model to assess antimycobacterial immunity induced by [CONTACT_349832] a candidate tuberculosis vaccine, MVA85A, alone and in combinat ion. J Infect Dis. 2014 Apr 15;209(8):1259- 68. PMID 24273174.  
27. Minhinnick A, Harris S, Wilkie M, Peter J, Stockdale L, … McShane H . Optimization of a Human Bacille 
Calmette -Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.  J Infect Dis.  2016 
Mar 1;213(5):824 -30. PMID 26450421.  
28. Hoft DF, Leonardi C, Milligan T, Nahass GT, Kemp B, … Carey M.  Clinical reactogenicity of intradermal 
bacille Calmette -Guérin vaccination.  Clin Infect Dis. 1999 Apr;28(4):785- 90. PMID 10825039.  
29. Blazevic A, Xia M, T uran A, Tennant J, Hoft DF.  Pi[INVESTIGATOR_116379] a human BCG challenge model.  
Tuberculosis (Edinb). 2017 Jul;105:108 -112. PMID 28610781 . 
 
  
 
Kublin_ Phase I human B CG challenge  trial                    Page 39 of 41    
Version: 03/29/2022  
 22.0 APPENDICES  
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 40 of 41    
Version: 03/29/2022  
  
Appendix A: Lab Procedures Table  
 
 
 
Visit: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Day: D0 D1 D2 D3 D4 D5 D6 D8 D 15 D28 D56 D84 D98 D100 D112 D114
Week: W0 W0 W0 W0 W0 W0 W0 W1 W2 W4 W8 W1 2 W14 W14 W16 W16
BCG — — Biopsy INH I NH INH — — — — — — — — —
Procedure Ship to TubeTube size 
(vol. 
capacity)
BLOOD COLLECTION
Screening or diagnostic  assays
     IGRA Local Lab Local Lab EDTA 5mL 4 — — — — — — — — — — — — 4 — 4 — [ADDRESS_434913] Local Lab Local Lab EDTA 5mL 5 — — — — — — — — — — — — — — — — 5
     HBsAg/anti-HCV Local Lab Local Lab SST 5mL 5 — — — — — — — — — — — — — — — — 5
     [COMPANY_003] ? ? — Injection — — — — — — — — — — — — — X X X X 0
S
afety labs
     CBC/ Diff/ platelets Local lab Local lab EDTA 5mL 5 — — — — — — — — — — — — — — — — [ADDRESS_434914] 5m L 5 — — — — — — — — — — — — — — — — [ADDRESS_434915] 5mL 5 — — — — — — — — — — — — — — — — 5
Immunogenicity & Mycobacteria assays
     HLA host genetics CSR FHCRC ACD 8.5mL — — — — — — — — — — — — — — — — — 0
     Cellular  assays — — — —
          ICS/ELISPOT / additional tests CSR FHCRC ACD 8.5mL — 51 — — — — — — 51 — 51 51 51 — — — 51 306
     Humoral assays
           Ab Assays / additional tests CSR ? SST 8.5mL — 17 — — — — — — 17 — 17 17 17 — — — 17 102
     Mycobacteria assays
          BCG PCR CSR UW — — — — — — X — — X X X — — — — — — [ADDRESS_434916] — Biopsy — — — — — X — — X X X — — — — — — 0
     Innate Immunity 
          Serum Cytokines CSR ? SST 3.5mL — 3.5 3.5 3 .5 3.5 3.5 — — 3.5 3.5 3.5 3.5 3.5 — — — — 35
          Whole Blood Gene Expression CSR ? Tempus 3mL — 3 3 3 3 3 — — 3 3 3 3 3 — — — — 30
STORAGE
     PBMC CSR FHCRC ACD 8.5mL — 40 — — — — — — — 50 20 20 20 — — — 70 220
Visit total 29 114.5 6.5 6.5 6 .5 6.5 74.5 56.5 94.5 94.5 94.5 4 0 4 138 730
56-Day total 29 143.5 150 156.5 163 169. 5 244 300.5 395 489.5 283.5 193 193 197 240.5
URINE COLLECTION
      Urinalysis Local lab Local lab X — — — — — — — — — — — — — — —
      P
regnancy test Local lab Local lab X — — — — — — — — — — — — — — —
      Chlamydia/Gonorrhea Local lab Local lab X — — — — — — — — — — — — — — —Tube volume (mL)
TotalScreening 
visit
 
 
Kublin_ Phase I human B CG challenge  trial                    Page 41 of 41    
Version: 03/29/2022  
 Appendix B: Participant Procedures Table
 
 * Only if applicable due to medical history and clinical assessment  
  O = microbiology 
  X = immunology  
  S = swab  Clinic Visit1 
(Screening 
Visit)2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Day -42 to -1 0 1 2 3 4 5 6 8 +1 15+1 28+1 56+2 84+3 98[PHONE_7236] [PHONE_7237] [PHONE_7238] +1
Week 1 2 4 8 12
Agents BCG INH INH INH
Informed consent X
M edical histor y X
Height, weight: BMI X
Vitals (pulse, blood 
pres s ure)X
Ur ine collection X
Pregnancy test (blood) X
Pregnancy test (urine)24 hr before 
to BCG dose
Gener al ex am and 
C linical assessmentX X* X* X* X* X* X* X
Lymphadenopathy 
assessmentX* X* X* X* X* X*
BC G injection site 
ev aluationX X X X X X X X X X X X
Abnormal BCG injection site 
Abnormal BCG injection site 
clinic visits
Abnormal BCG injection site 
photos
Health status and 
AE/SAE reviewX X X X X X X X X X X X X X X X
Concomitant med review X X X X X X X X X X X X X
Ora l  tempera ture 
reporti ngX
AE/SAE reporti ng 
C oncomitant medication 
reporti ng
ID site pain, tenderness, 
drainage reporting
Blood draw X X X X X X X X X X X X X X
Skin biopsy O/S X/S O/S X/S
Photographs of ID site X X X X X X X
[COMPANY_003] s ki n tes t X X X X
Dressing/guaze 
collectionX X X X X X X X X
* Only  if applicable due to medical histor y  and clinical assessment
O = microbiology
X = immunologyS = swabDays 1 - 112 (recorded on Memory Aid eCRF device)
Days 1 - 114 (recorded on Memory Aid eCRF device)
Days 1 - 114 (recorded on Memory Aid eCRF device)
Days 1- 114 (recorded on Memory Aid eCRF device)0 14 16
See section 11.3 for procedures
Clinic visits 2x/week from Day 28 +1  until resolved
Once/week from Days 28 +1 until resolved